Harm brings over 20 years of expertise in strategy and corporate finance in life sciences. He has led strategic planning functions at mid-cap biotechs Alkermes Plc and Elan Plc, holding responsibilities that included long term strategic planning, corporate finance, revenue forecasting, portfolio management and business performance optimisation, as well as M&A assessments and deal structuring. Prior to these roles, Harm honed his analytical skills at Arthur Andersen/Deloitte, consulting on financial due diligence investigations and M&A transactions.  Harm holds an Msc in Management & Organisation from Rijksuniversiteit Groningen as well as a Trinity College MBA and is an IoD certified director.

Neil has over two decades of leadership experience in life sciences, health technology, and software development. He has been instrumental in transforming companies at pivotal moments, most recently as Chief Commercial Officer at Datalex plc. Previously, Neil was Chief Operating Officer and founding team member at life sciences investment business Malin plc. During his decade at Elan plc, Neil ultimately led M&A operations at the time of the biotech's strategic sale in 2013. Neil is a Barrister, a graduate of University of Galway (B.Comm) and the Honorable Society of King’s Inns (BL) and is a Fellow of the Chartered Governance Institute.